| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash | 1,876,626 | - | ||
| Employee advances | 41,852 | - | ||
| Prepaid expenses | 403,213 | 751,963 | ||
| Cash | - | 2,802,013 | ||
| Total current assets | 2,321,691 | 3,553,976 | ||
| Fixed assets (net) | 3,185 | 3,880 | ||
| Patents (net of amortization) | 6,628,375 | 6,752,619 | ||
| Total assets | 8,953,251 | 10,310,475 | ||
| Accounts payable | 3,374,287 | 2,702,724 | ||
| Accrued expenses | 395,450 | 380,310 | ||
| Warrant liability | - | 0 | ||
| Accrued payroll and payroll taxes | 614 | - | ||
| Accrued payroll and payroll taxes related party | - | 0 | ||
| Preferred dividends payable | 375,000 | 375,000 | ||
| Total current liabilities | 4,145,351 | 3,458,034 | ||
| Tedco grant | 100,000 | 100,000 | ||
| Total long-term liabilities | 100,000 | 100,000 | ||
| Total liabilities | 4,245,351 | 3,558,034 | ||
| Series a convertible preferred stock, par value 0.001, 2,500,000 shares authorized 392,500 and 1,512,500 issued and outstanding, respectively | 1,070,705 | 1,808,794 | ||
| Total mezzanine equity | 1,070,705 | 1,808,794 | ||
| Common stock a, par value 0.001, 50,000,000 shares authorized 33,269,981 and 20,869,908 issued and outstanding, respectively | 33,270 | 29,665 | ||
| Additional paid-in capital | 57,329,311 | 51,759,838 | ||
| Accumulated deficit | -53,725,386 | -46,845,856 | ||
| Total stockholders equity (deficit) | 3,637,195 | 4,943,647 | ||
| Total liabilities, mezzanine equity and stockholders equity (deficit) | 8,953,251 | 10,310,475 | ||
OS Therapies Inc (OSTX)
OS Therapies Inc (OSTX)